635 related articles for article (PubMed ID: 26477842)
1. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
Berg K; Pedersen TR; Sandvik L; Bragadóttir R
Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.
Jaffe GJ; Eliott D; Wells JA; Prenner JL; Papp A; Patel S
Ophthalmology; 2016 Jan; 123(1):78-85. PubMed ID: 26499921
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
7. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
[TBL] [Abstract][Full Text] [Related]
8. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration.
Chin-Yee D; Eck T; Fowler S; Hardi A; Apte RS
Br J Ophthalmol; 2016 Jul; 100(7):914-917. PubMed ID: 26516125
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
Waldstein SM; Wright J; Warburton J; Margaron P; Simader C; Schmidt-Erfurth U
Ophthalmology; 2016 Jan; 123(1):60-9. PubMed ID: 26481821
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review.
Solomon SD; Lindsley KB; Krzystolik MG; Vedula SS; Hawkins BS
Ophthalmology; 2016 Jan; 123(1):70-77.e1. PubMed ID: 26477843
[TBL] [Abstract][Full Text] [Related]
12. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
13. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.
Holz FG; Tadayoni R; Beatty S; Berger A; Cereda MG; Hykin P; Staurenghi G; Wittrup-Jensen K; Altemark A; Nilsson J; Kim K; Sivaprasad S
Br J Ophthalmol; 2016 Dec; 100(12):1623-1628. PubMed ID: 27030279
[TBL] [Abstract][Full Text] [Related]
14. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.
Berg K; Roald AB; Navaratnam J; Bragadóttir R
Acta Ophthalmol; 2017 Dec; 95(8):796-802. PubMed ID: 28926190
[TBL] [Abstract][Full Text] [Related]
15. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.
Shona O; Gupta B; Vemala R; Sivaprasad S
Clin Exp Ophthalmol; 2011 Jan; 39(1):5-8. PubMed ID: 21040311
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
[TBL] [Abstract][Full Text] [Related]
17. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
Silva R; Berta A; Larsen M; Macfadden W; Feller C; Monés J;
Ophthalmology; 2018 Jan; 125(1):57-65. PubMed ID: 28893454
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
Jackson TL; Chakravarthy U; Kaiser PK; Slakter JS; Jan E; Bandello F; O'Shaughnessy D; Gertner ME; Danielson L; Moshfeghi DM;
Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
[TBL] [Abstract][Full Text] [Related]
19. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
[TBL] [Abstract][Full Text] [Related]
20. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
